Asset
Amdizalisib
HUTCHMED (China) Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02631642 | phase1 | completed | 2016-03-23 | 2016-10-26 | Hutchison Medipharma Limited | A Study of HMPL-689 in Healthy Volunteers |
| NCT03128164 | phase1 | completed | 2017-08-08 | 2023-08-02 | Hutchison Medipharma Limited | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed |
| NCT05713110 | phase2 | completed | 2023-02-13 | 2024-12-31 | Hutchmed | A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma |
| NCT04849351 | phase2 | completed | 2021-04-15 | 2024-02-29 | Hutchison Medipharma Limited | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
| NCT03786926 | phase1 | terminated | 2019-08-26 | 2024-06-26 | Hutchmed | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas |
FDA applications (0)
This company has no applications containing this asset.